A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

241

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

June 22, 2023

Study Completion Date

July 3, 2023

Conditions
Inflammation Eye PainPostoperative Cataract
Interventions
DRUG

OCS-01

Dexamethasone ophthalmic suspension, 1.5%

DRUG

Vehicle

Vehicle

Trial Locations (25)

18704

Oculis Site 7, Kingston

24502

Oculis Site 30, Lynchburg

28501

Oculis Site 13, Kinston

30260

Oculis Site 17, Morrow

33321

Oculis Site 12, Tamarac

40206

Oculis Site 20, Louisville

44141

Oculis Site 6, Brecksville

45242

Oculis Site 14, Cincinnati

63090

Oculis Site 3, Washington

63128

Oculis Site 5, St Louis

72704

Oculis Site 8, Fayetteville

77025

Oculis Site 10, Houston

78229

Oculis Site 2, San Antonio

Oculis Site 31, San Antonio

78731

Oculis Site 4, Austin

80528

Oculis Site 11, Fort Collins

84032

Oculis Site 27, Salt Lake City

85003

Oculis Site 28, Phoenix

85224

Oculis Site 16, Chandler

90301

Oculis Site 9, Inglewood

90731

Oculis Site 24, San Pedro

92663

Oculis Site 23, Newport Beach

92683

Oculis Site 22, Westminster

94954

Oculis Site 26, Petaluma

97401

Oculis Site 25, Eugene

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oculis

INDUSTRY